PA
MLYS icon

Parallel Advisors’s Mineralys Therapeutics MLYS Stock Holding History

Parallel Advisors’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$594 Hold
22
– – ﹤0.01% 3767
2026
Q1 		$596 Hold
22
– – ﹤0.01% 3640
2025
Q4 		$798 Hold
22
– – ﹤0.01% 3334
2025
Q3 		$834 Hold
22
– – ﹤0.01% 3264
2025
Q2 		$298 Hold
22
– – ﹤0.01% 3378
2025
Q1 		$349 Hold
22
– – ﹤0.01% 3300
2024
Q4 		$271 Hold
22
– – ﹤0.01% 3334
2024
Q3 		$266 Hold
22
– – ﹤0.01% 3256
2024
Q2 		$257 Hold
22
– – ﹤0.01% 3175
2024
Q1 		$284 Sell
22
-137
-86% -$1.69K ﹤0.01% 3119
2023
Q4 		$1.37K Buy
+159
New +$1.25K ﹤0.01% 2878

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AP
Andera Partners Paris $206M AUM
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

Parallel Advisors's MLYS Position: Q2 2026 in Review

Parallel Advisors held its Mineralys Therapeutics (MLYS) position steady in Q2 2026 at 22 shares worth $594. The position accounts for ﹤0.01% of the portfolio, ranked #3767.

Parallel Advisors first reported a position in MLYS in Q4 2023 and has held it in 11 quarters since. The position peaked at $1.37K in Q4 2023. 58 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

  • Parallel Advisors held 22 shares of Mineralys Therapeutics worth $594 as of Q2 2026.
  • Parallel Advisors left its Mineralys Therapeutics share count unchanged in Q2 2026.
  • Mineralys Therapeutics made up ﹤0.01% of Parallel Advisors's portfolio in Q2 2026, its #3767 holding.
  • Parallel Advisors first reported a position in Mineralys Therapeutics in Q4 2023 and has held it in 11 quarters since.
  • Parallel Advisors's Mineralys Therapeutics position peaked at $1.37K in Q4 2023.
  • 58 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on Parallel Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.